SCHEMBL2800543

SCHEMBL2800543

Cc1ccc(F)c(Nc2c(C(=O)N3CCC(c4ccc5ccccc5c4)CC3)cnc3c(C(=O)O)cnn23)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.37
DHODH Q02127 5/20 0.37
CCKAR P32238 2/20 0.36
MT-CO1 P00395 1/20 0.36
CNR2 P34972 1/20 0.36
SPR P35270 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35
GUCY1A1 Q02108 1/20 0.35
GUCY1B1 Q02153 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
HCRTR1 O43613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801655 0.92 ALDH1A1 (0.41) EGLN1SPRALDH1A1KDM4EMEN1
SCHEMBL2801212 0.91 DHODH (0.37) EGLN1DHODHSPRALDH1A1KDM4E
SCHEMBL2801458 0.91 KDM4E (0.39) CCKARALDH1A1KDM4EMEN1TSHR
SCHEMBL2799735 0.90 FASN (0.40) EGLN1DHODHALDH1A1TP53MAPT
SCHEMBL2802313 0.89 EGLN1 (0.35) EGLN1SPRALDH1A1KDM4EMEN1
SCHEMBL2800966 0.88 FASN (0.40) EGLN1DHODHCCKARMT-CO1CNR2
SCHEMBL2801551 0.87 FASN (0.39) DHODHSPRALDH1A1KDM4EHSD17B10
SCHEMBL2802498 0.84 ALDH1A1 (0.40) EGLN1SPRALDH1A1KDM4EMEN1
SCHEMBL2799436 0.84 TP53 (0.44) SPRALDH1A1KMT2ATP53MAPT
SCHEMBL2803138 0.83 TP53 (0.42) DHODHALDH1A1TP53MAPTHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 EGLN1 1967/4885DHODH 446/4885CCKAR 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.